Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Diovan/Co-Diovan was produced by Novartis.

Novartis lifts 2013 guidance on delay to Diovan generics

Novartis lifts 2013 guidance on delay to Diovan generics Reveals scale of payments to former CEO Daniel Vasella. A delay to the launch of a generic version of Novartis' high blood pressure drug Diovan has caused the pharma company to ... Diovan lost 22 per cent but still brought in $928m in the quarter, while

Novartis expects tough 2013 before a return to growth

Novartis expects tough 2013 before a return to growth Says it will take a year for new medicine sales  to overcome Diovan patent loss. ... to the expected impact of generic completion for the blood pressure treatment Diovan (valsartan).

Country report: The healthcare market in Japan

Country report: The healthcare market in Japan Diovan. valsartan. Novartis. Hypertension. 4. Cervarix. human papillomavirus (HPV) vaccine. GlaxoSmithKline.

Pharma's biggest news stories in 2011

Other companies to face up to patent losses over 2011 include Novartis, which lost exclusive rights to market its blood pressure drug Diovan (valsartan), although the drug remained its biggest seller

EU approval for Takeda's once-daily hypertension drug Edarbi

In comparison trials with the rival ARBs, Daiichi Sankyo's Olmetec (olmesartan medoxomil) and Novartis' Diovan (valsartan), as well as the ACE inhibitor ramipril, use of Edarbi resulted in significantly greater ... Top selling products in the therapy

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...